About Vera Therapeutics, Inc.
https://veratx.comVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
CEO
Marshall W. Fordyce
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 129
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Goldman Sachs
Buy
B of A Securities
Buy
TD Cowen
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Evercore ISI Group
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
AVORO CAPITAL ADVISORS LLC
Shares:6.21M
Value:$300.63M
BLACKROCK, INC.
Shares:4.25M
Value:$205.61M
KYNAM CAPITAL MANAGEMENT, LP
Shares:4.03M
Value:$194.99M
Summary
Showing Top 3 of 197
About Vera Therapeutics, Inc.
https://veratx.comVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $83.37M ▲ | $-80.29M ▼ | 0% | $-1.26 ▼ | $-77.77M ▼ |
| Q2-2025 | $0 | $79.58M ▲ | $-76.53M ▼ | 0% | $-1.2 ▼ | $-74.09M ▼ |
| Q1-2025 | $0 | $57.19M ▲ | $-51.69M ▼ | 0% | $-0.81 ▲ | $-49.82M ▼ |
| Q4-2024 | $0 | $48.91M ▼ | $-43.42M ▲ | 0% | $-0.85 | $-41.5M ▲ |
| Q3-2024 | $0 | $49.8M | $-46.63M | 0% | $-0.85 | $-44.67M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $497.39M ▼ | $517.5M ▼ | $118.62M ▲ | $398.88M ▼ |
| Q2-2025 | $556.83M ▼ | $578.53M ▼ | $110.25M ▲ | $468.28M ▼ |
| Q1-2025 | $589.83M ▼ | $610.17M ▼ | $75.17M ▼ | $535M ▼ |
| Q4-2024 | $640.85M ▲ | $655.68M ▲ | $78.53M ▼ | $577.15M ▲ |
| Q3-2024 | $353.31M | $368.56M | $79.5M | $289.06M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-80.29M ▼ | $-61.91M ▼ | $69.76M ▲ | $797K ▼ | $8.65M ▲ | $-62.04M ▼ |
| Q2-2025 | $-76.53M ▼ | $-54.8M ▼ | $28.54M ▲ | $20.29M ▲ | $-5.97M ▲ | $-55.01M ▼ |
| Q1-2025 | $-51.69M ▼ | $-54.41M ▼ | $15.32M ▲ | $1.53M ▼ | $-37.56M ▼ | $-54.59M ▼ |
| Q4-2024 | $-43.42M ▲ | $-39.18M ▼ | $-221.38M ▼ | $325.95M ▲ | $65.39M ▲ | $-39.83M ▲ |
| Q3-2024 | $-46.63M | $-36.88M | $38.32M | $739K | $2.17M | $-61.99M |
CEO
Marshall W. Fordyce
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 129
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Goldman Sachs
Buy
B of A Securities
Buy
TD Cowen
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Evercore ISI Group
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
AVORO CAPITAL ADVISORS LLC
Shares:6.21M
Value:$300.63M
BLACKROCK, INC.
Shares:4.25M
Value:$205.61M
KYNAM CAPITAL MANAGEMENT, LP
Shares:4.03M
Value:$194.99M
Summary
Showing Top 3 of 197